BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 24097105)

  • 1. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
    Hoelzer D
    Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoimmunotherapy in acute lymphoblastic leukemia.
    Hoelzer D; Gökbuget N
    Blood Rev; 2012 Jan; 26(1):25-32. PubMed ID: 21958552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects.
    Gökbuget N; Hoelzer D
    Ann Hematol; 2004 Apr; 83(4):201-5. PubMed ID: 14648023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antibody-based therapy for acute lymphoblastic leukaemia.
    Gökbuget N; Hoelzer D
    Best Pract Res Clin Haematol; 2006; 19(4):701-13. PubMed ID: 16997178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of antibody therapy in ALL.
    Ai J; Advani A
    Br J Haematol; 2015 Feb; 168(4):471-80. PubMed ID: 25382151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
    Farhadfar N; Litzow MR
    Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
    J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.
    Litzow MR
    Am Soc Clin Oncol Educ Book; 2013; ():294-9. PubMed ID: 23714527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.
    Le Jeune C; Thomas X
    Eur J Haematol; 2015 Feb; 94(2):99-108. PubMed ID: 24981395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging biological therapies to treat acute lymphoblastic leukemia.
    Huguet F; Tavitian S
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel antibody-based therapies for acute lymphoblastic leukemia.
    Hoelzer D
    Hematology Am Soc Hematol Educ Program; 2011; 2011():243-9. PubMed ID: 22160041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies in acute lymphoblastic leukemia.
    Jabbour E; O'Brien S; Ravandi F; Kantarjian H
    Blood; 2015 Jun; 125(26):4010-6. PubMed ID: 25999456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody therapy for acute lymphoblastic leukemia.
    Portell CA; Advani AS
    Curr Hematol Malig Rep; 2012 Jun; 7(2):153-9. PubMed ID: 22422550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early relapse after rituximab chemoimmunotherapy.
    Kiss F; Buslig J; Szegedi I; Scholtz B; Kappelmayer J; Kiss C
    Pediatr Blood Cancer; 2008 Feb; 50(2):372-5. PubMed ID: 17973316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C; Thomas X
    Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches.
    Locatelli F; Moretta F; Rutella S
    Curr Opin Oncol; 2013 Nov; 25(6):707-15. PubMed ID: 24076579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies in adult acute lymphoblastic leukemia.
    Kantarjian H
    Hematology; 2012 Apr; 17 Suppl 1():S52-4. PubMed ID: 22507779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.
    Rayes A; McMasters RL; O'Brien MM
    Pediatr Blood Cancer; 2016 Jun; 63(6):1113-5. PubMed ID: 26914337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody based therapy in relapsed acute lymphoblastic leukemia.
    Jammal N; Chew S; Jabbour E; Kantarjian H
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.